Fixed Dosing of Liposomal Amphotericin B in Morbidly Obese Individuals

Clin Infect Dis. 2020 May 6;70(10):2213-2215. doi: 10.1093/cid/ciz885.


In this prospective study, we examined the pharmacokinetics of 1 and 2 mg/kg liposomal amphotericin B in 16 morbidly obese individuals (104-177 kg). Body size had no effect on clearance. We recommend a fixed dose in patients ≥100 kg (ie, 300 or 500 mg rather than the current dose of 3 and 5 mg/kg, respectively). Clinical Trials Registration NCT02320604.

Keywords: fungal infection; fungal treatment; obese; optimal dosing; population pharmacokinetics.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amphotericin B
  • Antifungal Agents* / therapeutic use
  • Humans
  • Obesity, Morbid* / complications
  • Obesity, Morbid* / drug therapy
  • Prospective Studies


  • Antifungal Agents
  • liposomal amphotericin B
  • Amphotericin B

Associated data